User profiles for Matthew F Pullen
 | Matthew PullenAssistant Professor of Internal Medicine/Infectious Diseases, University of Minnesota Verified email at umn.edu Cited by 3060 |
A randomized trial of hydroxychloroquine as postexposure prophylaxis for Covid-19
DR Boulware, MF Pullen, AS Bangdiwala… - New England journal …, 2020 - Mass Medical Soc
Background Coronavirus disease 2019 (Covid-19) occurs after exposure to severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2). For persons who are exposed, the …
respiratory syndrome coronavirus 2 (SARS-CoV-2). For persons who are exposed, the …
Hydroxychloroquine in nonhospitalized adults with early COVID-19: a randomized trial
…, DA Williams, EC Okafor, MF Pullen… - Annals of internal …, 2020 - acpjournals.org
Background: No effective oral therapy exists for early coronavirus disease 2019 (COVID-19).
Objective: To investigate whether hydroxychloroquine could reduce COVID-19 severity in …
Objective: To investigate whether hydroxychloroquine could reduce COVID-19 severity in …
Randomized trial of metformin, ivermectin, and fluvoxamine for Covid-19
…, HG Saveraid, WJ Tordsen, MF Pullen… - … England Journal of …, 2022 - Mass Medical Soc
Background Early treatment to prevent severe coronavirus disease 2019 (Covid-19) is an
important component of the comprehensive response to the severe acute respiratory …
important component of the comprehensive response to the severe acute respiratory …
[HTML][HTML] Outpatient treatment of COVID-19 and incidence of post-COVID-19 condition over 10 months (COVID-OUT): a multicentre, randomised, quadruple-blind …
…, CJ Tignanelli, JL Thompson, M Pullen… - The Lancet Infectious …, 2023 - thelancet.com
Background Post-COVID-19 condition (also known as long COVID) is an emerging chronic
illness potentially affecting millions of people. We aimed to evaluate whether outpatient …
illness potentially affecting millions of people. We aimed to evaluate whether outpatient …
Hydroxychloroquine and chloroquine for treatment of SARS-CoV-2 (COVID-19)
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a rapidly emerging viral
infection causing coronavirus disease 2019 (COVID-19). Hydroxychloroquine and …
infection causing coronavirus disease 2019 (COVID-19). Hydroxychloroquine and …
Hydroxychloroquine as pre-exposure prophylaxis for coronavirus disease 2019 (COVID-19) in healthcare workers: a randomized trial
…, KA Pastick, ML Axelrod, MF Pullen… - Clinical Infectious …, 2021 - academic.oup.com
Background Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a rapidly
emerging virus causing the ongoing coronavirus disease 2019 (COVID-19) pandemic with no …
emerging virus causing the ongoing coronavirus disease 2019 (COVID-19) pandemic with no …
Symptoms of COVID-19 outpatients in the United States
MF Pullen, CP Skipper, KH Hullsiek… - Open forum …, 2020 - academic.oup.com
Background Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is a novel
pathogen causing the current worldwide coronavirus disease 2019 (COVID-19) pandemic. Due …
pathogen causing the current worldwide coronavirus disease 2019 (COVID-19) pandemic. Due …
Safety of hydroxychloroquine among outpatient clinical trial participants for COVID-19
…, EC Okafor, CP Skipper, MF Pullen… - Open forum …, 2020 - academic.oup.com
Background Use of hydroxychloroquine in hospitalized patients with coronavirus disease
2019 (COVID-19), especially in combination with azithromycin, has raised safety concerns. …
2019 (COVID-19), especially in combination with azithromycin, has raised safety concerns. …
[HTML][HTML] Metformin reduces sars-cov-2 in a phase 3 randomized placebo controlled clinical trial
…, SM Erickson, RD Fricton, S Lee, G Griffiths, MF Pullen… - medRxiv, 2023 - ncbi.nlm.nih.gov
Current antiviral treatment options for SARS-CoV-2 infections are not available globally, cannot
be used with many medications, and are limited to virus-specific targets. 1–3 Biophysical …
be used with many medications, and are limited to virus-specific targets. 1–3 Biophysical …
[HTML][HTML] Post-exposure prophylaxis or pre-emptive therapy for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): study protocol for a pragmatic …
…, EC Okafor, KA Pastick, MF Pullen… - Canadian Journal of …, 2020 - ncbi.nlm.nih.gov
Background The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged
in December 2019 causing the coronavirus disease (COVID-19) pandemic. Currently, there …
in December 2019 causing the coronavirus disease (COVID-19) pandemic. Currently, there …
